BGNE:NSD-BeiGene Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 132.87

Change

0.00 (0.00)%

Market Cap

USD 13.57B

Volume

0.42M

Avg Analyst Target

USD 301.00 (+126.54%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BeiGene Ltd (BGNE) Stock Analysis:
Based on the BeiGene Ltd stock forecasts from 4 analysts, the average analyst target price for BeiGene Ltd is USD 301.00 over the next 12 months. BeiGene Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BeiGene Ltd is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, BeiGene Ltd’s stock price was USD 132.87. BeiGene Ltd’s stock price has changed by -9.79% over the past week, -27.14% over the past month and -58.43% over the last year.

About

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer therapeutics in the People's Republic of China, the United States, and internationally. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD63.10B 27.38 17.74
MRNA Moderna Inc

N/A

USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.40B 3.79 1.55
RPRX Royalty Pharma plc

N/A

USD26.93B 26.81 14.86
SGEN Seagen Inc

N/A

USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD18.31B 43.41 4.62
ARGX argenx SE

N/A

USD16.90B N/A N/A

ETFs Containing BGNE

Symbol Name Weight Mer Price(Change) Market Cap
EMMV:PA Ossiam Lux - Ossiam Emerg.. 3.76 % 0.75 %

N/A

N/A
DEMV:LSE Ossiam Lux - Ossiam Emerg.. 3.76 % 0.75 %

N/A

USD0.92M
OSX9:XETRA Ossiam Lux - Ossiam Emerg.. 3.76 % 0.75 %

N/A

USD8.35M
CHB Global X China Biotech In.. 0.00 % 0.65 %

N/A

N/A
FLHK Franklin FTSE Hong Kong E.. 0.00 % 0.09 %

N/A

USD0.02B
KURE KraneShares MSCI All Chin.. 0.00 % 0.65 %

N/A

USD0.12B
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.55 %

N/A

USD0.09B
CHNA ETF Series Solutions - Lo.. 0.00 % 0.79 %

N/A

USD7.46M
CHNA ETF Series Solutions - Lo.. 0.00 % 0.79 %

N/A

USD7.46M
KMED KraneShares Emerging Mark.. 0.00 % 0.80 %

N/A

USD2.26M
CHIH Global X MSCI China Healt.. 0.00 % 0.65 %

N/A

USD0.01B
GDNA Goldman Sachs Human Evolu.. 0.00 % 0.50 %

N/A

USD0.06B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.04B
ETLI:XETRA Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.04B
BIOT Biotech Acquisition Compa.. 0.00 % 0.75 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.96% 44% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.96% 44% F 23% F
Trailing 12 Months  
Capital Gain -58.43% 55% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.43% 55% F 26% F
Trailing 5 Years  
Capital Gain 250.21% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 250.21% 91% A- 91% A-
Average Annual (5 Year Horizon)  
Capital Gain 47.66% 79% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.66% 79% C+ 88% B+
Risk Return Profile  
Volatility (Standard Deviation) 79.81% 34% F 18% F
Risk Adjusted Return 59.71% 93% A 84% B
Market Capitalization 13.57B 98% A+ 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.12 40% F 39% F
Price / Cash Flow Ratio -10.45 83% B 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -27.95% 80% B- 32% F
Return on Invested Capital -25.11% 79% C+ 30% F
Return on Assets -12.61% 83% B 28% F
Debt to Equity Ratio 3.24% 75% C 82% B-
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.40 22% F 11% F
Short Percent 5.88% 41% F 29% F
Beta 0.76 76% C 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector